Tumor Heterogeneity: From Single Cells to Clinical Impact
September 10-13, 2020
AACR Virtual Special Conference
Notice of Termination and Rescheduling
The American Association for Cancer Research (AACR) has made the difficult decision, after careful consideration and a comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, to terminate the AACR Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact, originally scheduled for September 10–13, 2020, in Philadelphia, Pennsylvania. A rescheduled virtual meeting is being planned.
We recognize that the new data, exchange of information, and opportunities for collaboration offered by this meeting are highly valued by the cancer research community; therefore, we are working to reschedule the meeting as a virtual event over the dates of the originally scheduled program.
Information on the rescheduled meeting will be sent by email once it becomes available. All meeting registrations will be refunded by August 1. If you have a room reservation at the Sheraton Philadelphia Downtown, please cancel your reservation as soon as possible by contacting the hotel at (215) 448-2000. Many airlines have adjusted their rebooking and cancellation policies in response to the COVID-19 crisis. Please contact your airline or booking agent directly to cancel your travel arrangements to Philadelphia.
Abstracts that were submitted for the meeting are currently under review and, if accepted, will be included for presentation in the rescheduled virtual meeting. If you wish to withdraw an abstract, please email your request to [email protected].
There will also be an opportunity for colleagues to submit abstracts for presentation at the virtual meeting. Please watch for an announcement pertaining to the deadline for abstract submission.
The AACR deeply appreciates your patience and understanding during this unfortunate situation. Please look for emails in the coming months as we work to reschedule this program as soon as possible. If you have any questions, please email [email protected].
Our heartfelt sympathies go out to everyone who has been impacted by this global health crisis. Thank you for your dedication to the AACR and to its mission.
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, Massachusetts
Alexander K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom
Tumors are composed of heterogeneous populations of cells that possess distinct genetic, morphological, and phenotypic profiles, which in turn can impact tumor development, treatment response, and therapeutic resistance. Additionally, even tumors with similar profiles may react differently depending on their microenvironment. This conference will bring together the top basic, translational, and clinical researchers in the field of tumor heterogeneity. Presentations will feature the most recent research on basic biological mechanisms, new technological and computational developments, approaches to targeting and monitoring heterogeneity, and the implications of these findings for the clinical setting.